Trial Profile
A phase IIIb, open label, randomized, exploratory clinical study exploring efficacy, safety and patients satisfaction with Certolizumab pegol treatment in moderate to severe Crohn's disease when treatment is administered in two different settings : either at hospital or at home.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 Jul 2012
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms PERFECT
- Sponsors UCB Pharma SA
- 27 Jul 2011 New trial record